Characterization of [3H]nisoxetine binding in rat vas deferens membranes: Modulation by sigma and PCP ligands

Life Sciences

Volumn 62, Issue 8, 1998, Pages 763-773

  Pubill, David ^a   Gasulla, Daniel ^a   Sureda, Francesc X ^a   Camins, Antonio ^a   Pallàs, Mercè ^a   Escubedo, Elena ^a   Camarasa, Jorge ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

3H nisoxetine; Noradrenaline transporter; PCP ligands; Sigma ligands; Vas deferens

Indexed keywords

DEXTROMETHORPHAN; DEXTRORPHAN; DIZOCILPINE; HALOPERIDOL; NISOXETINE; PHENCYCLIDINE; PHENCYCLIDINE RECEPTOR; PRECLAMOL; SIGMA OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; TENOCYCLIDINE; CARRIER PROTEIN; COTRANSPORTER; DRUG DERIVATIVE; FLUOXETINE; NORADRENALIN TRANSPORTER; SLC6A2 PROTEIN, RAT; SODIUM;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; ISOTOPE LABELING; MALE; NONHUMAN; RAT; VAS DEFERENS; ANIMAL; BINDING COMPETITION; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; FLUOXETINE; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PHENCYCLIDINE; RECEPTORS, SIGMA; SODIUM; SYMPORTERS; VAS DEFERENS;

EID: 0032535853     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)01174-0     Document Type: Article

References (42)

1. 1. A.C. FOSTER and G.E. FAGG, Nature 329 395-396 (1987).
2. 2. P.A. LOO, A.F. BRAUNWALDER, M. WILLIAMS and M.A. SILLS, Eur. J. P Pharmacol. 135 261-263 (1987).
3. 3. R.B. ROTHMAN. Neurotoxicol. Teratol. 16(4) 343-353 (1994).
4. 4 W.R. MARTIN, C.E. EADES, J.A. THOMPSON and R.E. HUPPLER, J. Pharmacol. Exp. Ther. 197 517-532 (1976).
5. 5 J.M. WALKER, W.D. BOWEN, F.O. WALKER, R.R. MATSUMOTO, B. DE COSTA and K.C. RICE, Pharmacol. Rev. 42 355-402 (1990).
6. 6. G. DEBONNEL and C. DE MONTIGNY, Life Sci, 58(9)721-734 (1996).
7. 7. P.J. GILLIGAN and S.W. TAM, Drug News Perspect. 7(1) 13-18 (1994).
8. 8 R.C. SMITH, H.Y. MELTZER, R.C. ARORA and J.M. DAVIS, Biochem. Pharmacol. 26 1435-1439 (1977).
9. 9. J.F. BOWYER, K.P. SPUHLER and N. WEINER, J. Pharmacol. Exp. Ther. 229 671-680 (1984).
10. 10. J. VIGNON and M. LAZDUNSKI, Biochem. Pharmacol. 33 700-702 (1984).
11. 11. K.M. JOHNSON and L.D. SNELL, Pharmacol. Biochem. Behav. 22 731-735 (1985).
12. 12. L.D. SNELL, S.J. YI and K.M. JOHNSON, Eur. J. Pharmacol. 145 223-226 (1988).
13. 13. C. ROGERS and S. LEMAIRE, Br. J. Pharmacol. 103 1917-1922 (1991).
14. 14 T. MASSAMIRI and S.P. DUCKLES, J. Pharmacol. Exp. Ther. 256(2) 519-524 (1991).
15. 15. C. ROGERS and S. LEMAIRE,Can. J. Physiol. Pharmacol. 70 1508-1514 (1992).
16. 16. T. MASSAMIRI and S.P. DUCKLES, J. Pharmacol. Exp. Ther. 253 (1) 124-129 (1990).
17. 17 B.G. CAMPBELL, D.H. BOBKER, F.M. LESLIE, I.N. MEFFORD and E. WEBER, Eur. J. Pharmacol. 138 447-449 (1987).
18. 18. D.B. VAUPEL and T.P. SU, Eur. J. Pharmacol. 139 125-128 (1987).
19. 19. P.K. FOX, L. FRANCE and C.D. NICHOLSON, Br. J. Pharmacol. 98 866 (1989).
20. 20. D. PUBILL, A.M. CANUDAS, D. GASULLA, M. PALLÀS, E. ESCUBEDO and J. CAMARASA, Eur. J. Pharmacol. 303 171-175 (1996).
21. 21. S.M. TEJANI-BUTT, D.J. BRUNSWICK and A. FRAZER, Eur. J. Pharmacol. 191 239-243 (1990).
22. 22. S.M. TEJANI-BUTT, J. Pharmacol. Exp. Ther. 260(1) 427-436 (1992).
23. 23. S.M. TEJANI-BUTT and G.A. ORDWAY, Brain Res. 583 312-315 (1992).
24. 24 L.D. JAYANTHI, P.D. PRASSAT, S. RAMAMOORTHY, V.B. MAHESH, F.H. LEIBACH and V. GANAPATHY, Biochemistry 32 12178-12185 (1993).
25. 25. M.M. BRADFORD, Anal. Biochem. 72 248-254 (1976).
26. 26. P.J. MUNSON and D. RODBARD, Anal. Biochem. 107 220-239 (1980).
27. 27. Y. Cheng and W.H. Prusoff, Biochem. Pharmacol. 22 3099-3108 (1973).
28. 28. M. REHAVI, P. SKOLNICK, B. HULIHAN and S.M. PAUL, Eur. J. Pharmacol. 70 597-599 (1981).
29. 29. C.M. LEE, J.A. JAVITCH and S.H. SNYDER, J. Neurochem. 2 1515-1525 (1982).
30. 30. E. SCHÖMIG and H. BÖNISCH, Naunyn-Schmiedeberg's Arch. Pharmacol. 337 626-632 (1986).
31. 31. I.T BACKSTROM, S.B. ROSS and J.O. MARCUSSON, J. Neurochem. 52 1099-1106 (1989).
32. 32. J.A. JAVITCH, R.O. BLAUSTEIN and S.H. SNYDER, Mol. Pharmacol. 26 35-44 (1984).
33. 33. J.A. JAVITCH, S.M. STRITTMATTER and S.H. SNYDER, J. Neurosci. 5 1513-1521 (1985).
34. 34. D.T. WONG, P.G. THRELKELD, K.L. BEST and F.P. BYMASTER, J. Pharmacol. Exp. Ther. 222 61-70 (1982).
35. 35. E. RICHELSON and M. PFENNING, Eur. J. Pharmacol. 104 277-286 (1984).
36. 36. E. RICHELSON and A. NELSON, J. Pharmacol. Exp. Ther. 230 94-102 (1984).
37. 37. D.M. WORRALL and D.C. WILLIAMS, Biochem. J. 297 425-436 (1994).
38. 38. C.J. ZEITNER and K.H. GRAEFE, Naunyn-Schmiedeberg's Arch. Pharmacol. 334 397-402 (1986).
39. 39. R. PEKELMANN and M.C. WERNECK, Naunyn-Schmiedeberg's Arch. Pharmacol. 346 405-409 (1992).
40. 40. R.B. ROTHMAN, A. REID, A. MAHBOUBI, C.H. KIM, B.R. DE COSTA, A.E. JACOBSON and K.C. RICE, Mol. Pharmacol. 39(2) 222-232 (1991).
41. 41. S. JACOBS, K.J. CHANG and P. CUATRECASAS, Biochem Biophys. Res. Commun. 66 687-692 (1975).
42. 42 P.K. FOX, J.H. CONNICK, G.M. HANLON, L. FRANCE and C.D. NICHOLSON, Eur. J. Pharmacol. 193 139-143 (1991).